ClinicalTrials.gg
RecruitingNCT06827301LOGICUpdated Feb 14, 2025

Transcutaneous Auricular Vagus Nerve Stimulation for Treating Post-stroke Dysphagia

An interventional study of Non Invasive vagus nerve stimulation in Dysphagia Following Cerebrovascular Accident, sponsored by Campus Bio-Medico University. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-14.

Sponsored by Campus Bio-Medico University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Nov 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Deglutition Disorders with a site in Italy — 11 open to participants now, 12 under way, none of them phase 3. Deglutition Disorders · Italy.

Planned enrollment
11th of 15
30 · median 60
Started
2024
with 3 others
No phase
14 of 27
3 open now
Primary completion
2025-12
later than 3 of 11 live
Registered
22nd of 27
by date
Lead sponsor
1 of 27
Campus Bio-Medico University

Among the 27 studies in Deglutition Disorders with a site in Italy, this one is the 11th largest by planned enrollment of the 15 interventional ones that give a count, is one of 4 that started in 2024, is one of 14 with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 22nd registered.

Deglutition Disorders

875 studies on the registry are indexed under Deglutition Disorders; 237 are open to participants now.

Browse Deglutition Disorders studies →

Open to participants now

11 of the 27 studies in Deglutition Disorders with a site in Italy are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 137 Deglutition Disorders studies recruiting now, 75 (55%) set no upper age limit and 26 (19%) stop at 75 or younger; 15 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Deglutition Disorders with a site in Italy, or all of them as a file.
02

Study summary

The aim of the present project is to use transcutaneous auricular vagus nerve stimulation (t-VNS) for the treatment of dysphagia in acute stroke patients to improve swallowing function and reduce mortality and disability related to this condition.

30 patients will be randomized into one of the two arms of the study:

  • REAL: real t-VNS + speech therapy
  • SHAM: t-VNS placebo + speech therapy. The experimental treatment consists in the association between t-VNS (real or placebo) and speech therapy exercises to improve swallowing functionality. Each patient will undergo a speech therapy rehabilitation session lasting approximately 40 minutes a day for 3 consecutive days, simultaneously with t-VNS on left ear.

Swallowing function and clinical conditions will be evaluated before the intervention (baseline, T0), immediately after the intervention (T1) and 3 months after the intervention (T2).

03

Conditions studied

  • Dysphagia Following Cerebrovascular Accident

Keywords

  • vagus nerve stimulation
  • dysphagia
  • stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute ischemic or hemorrhagic stroke (within 7 days of onset)
  • Dysphagia diagnosed by FEES with a Fiberoptic Endoscopic Dysphagia Severity Scale (FEDSS) score between 3 and 5

Exclusion criteria

Exclusion criteria:

  • Pre-existing stroke dysphagia
  • Dementia or other medical conditions that may interfere with the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Real t-VNS

    real t-VNS on left ear for 40 minutes, daily for 3 consecutive days, simultaneously with speech therapy.

    Device: Non Invasive vagus nerve stimulation

  • Active comparator
    Sham t-VNS

    sham t-VNS on left ear for 40 minutes, daily for 3 consecutive days, simultaneously with speech therapy.

    Device: Non Invasive vagus nerve stimulation

Interventions

  • DeviceNon Invasive vagus nerve stimulation

    Transcutaneous Auricular Vagus Nerve Stimulation

06

What researchers measure

Primary outcomes

  1. Swallowing function

    Swallowing video fluoroscopic will be used to measure swallowing function

    Time frame: Baseline, Immediately after intervention

Secondary outcomes

  1. Disability

    Disability will be measured by mRS and the necessity of nasogastric tube/gastrostomy.

    Time frame: Baseline, Immediately after intervention, 3 months after intervention

  2. Mortality

    Number of deaths

    Time frame: Baseline, Immediately after intervention, 3 months after intervention

  3. Morbidity

    Number of aspiration pneumonia

    Time frame: Baseline, Immediately after intervention, 3 months after intervention

  4. Swallowing function

    Swallowing video fluoroscopic will be used to measure swallowing function

    Time frame: Baseline, 3 months after intervention

07

Study locations

1 of 1 sites recruiting
  • Università Campus Bio-Medico di Roma
    Roma, RM 00128, Italy
    Recruiting
    • Vincenzo Di Lazzaro · Contactv.dilazzaro@unicampus.it · +3906225411220
    • Fioravante Capone, PhD · Contact
    • Fabio Pilato, MD · Contact
    • Vitaliana Luccarelli · Contact
    • Chiara Grattarola · Contact
    • Davide Norata, MD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2025, 13 months after the start.

Of 290 non-industry interventional studies with no phase under Deglutition Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 13 months is below that.

Counting every sponsor, half of 299 studies reached it within 21 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2024
First posted
Feb 14, 2025
StartActual
Nov 23, 2024
Primary completionEst.
Dec 2025
CompletionEst.
Jun 2026
Last update
Feb 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06827301
Lead sponsor
Campus Bio-Medico University
Responsible party
Di Lazzaro Vincenzo (Prof, Campus Bio-Medico University) — Principal investigator
First posted
Feb 14, 2025
Start date
Nov 23, 2024
Primary completion
Dec 2025 (estimated)
Completion
Jun 2026 (estimated)
Last update
Feb 14, 2025

Study contacts

Fioravante Capone, PhD
Contact
f.capone@policlinicocampus.it
06225411220
Fabio Pilato, MD
Contact
f.pilato@policlinicocampus.it

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion